Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumors.
No population pharmacokinetic studies of high-dose methotrexate (HDMTX) have been conducted in infants with brain tumors, which are a vulnerable population. The aim of this study was to evaluate HDMTX disposition in these children to provide a rational basis for MTX dosing. Patients received 4 monthly courses of HDMTX (5 g/m2 or 2.5 g/m2 for infants ≤ 31 days of age) as a 24-hour infusion. Serial samples were analyzed for MTX by an enzyme immunoassay method. Pharmacokinetic parameters were estimated using nonlinear mixed effects population modeling. Demographics, concomitant medications, and genetic polymorphisms were considered as pharmacokinetic covariates while MTX exposure and patient age were considered as covariates for Grade 3 and 4 toxicities. The population pharmacokinetics of HDMTX were estimated in 178 patients (age range 0.02 to 4.7 yr) in 648 courses. The population clearance and volume were 90 ml/min/m2 and 14.4 L/m2 , respectively. Significant covariates on body surface area adjusted MTX clearance included estimated glomerular filtration rate and co-treatment with dexamethasone or vancomycin. No significant association was observed between MTX toxicity and MTX exposure, patient age, leucovorin dosage or duration. MTX clearance in infants ≤ 31 days at enrollment was 44% lower than in older infants, but their incidence of toxicity was not higher since they also received a lower MTX dosage. By aggressively following institutional clinical guidelines, HDMTX-related toxicities were low, and using covariates from the population pharmacokinetic model enabled the calculation of a rational dosage for this patient population for future clinical trials.